Travere Therapeutics (TVTX) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Strategic focus and recent progress

• Focused on rare diseases: IgA nephropathy, FSGS, and homocystinuria, with significant progress in all three programs last year.

• FILSPARI is in its third year of launch for IgA nephropathy, showing strong commercial performance and aiming to become foundational care.

• sNDA for FILSPARI in FSGS is under FDA review, with a PDUFA date set for April 13 after an extension due to additional FDA information requests.

• Manufacturing scale-up challenges for HCU have been resolved, and the phase III HARMONY study is set to restart this quarter.

Regulatory and clinical updates

• High confidence in FILSPARI's approvability for FSGS, supported by strong pivotal study data showing superiority over irbesartan.

• FDA's late information requests were straightforward, and all have been addressed; awaiting draft labeling and potential approval.

• Noted FDA staff turnover and new reviewers, but strong engagement continues, with long-term involvement from the Cardiorenal Director.

• Will enter a quiet period in early March ahead of the PDUFA date.

Commercial strategy and market dynamics

• Anticipates rapid uptake of FILSPARI in FSGS due to urgent unmet need, strong execution, and nephrologist familiarity from IgA nephropathy.

• Expanded field team and high overlap (90%) between IgAN and FSGS prescribers; preparing to reach pediatric nephrologists for FSGS.

• Expects faster FSGS uptake compared to IgAN, driven by full approval, quarterly REMS, payer access, and urgency among patients and physicians.

• Competitive landscape in FSGS is evolving, but no direct competitors with the same mechanism are expected for several years.